Immunotherapy for post-transplant lymphoproliferative disease.
about
Immunotherapy of human cancers using gene modified T lymphocytes.Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Immunotherapy for Epstein-Barr virus-associated tumors.Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferationClinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea.Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)Posttransplant lymphoproliferative disease following liver transplantation.First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.CD4(+) T-cell responses to Epstein-Barr virus (EBV) latent membrane protein 1 in infectious mononucleosis and EBV-associated non-Hodgkin lymphoma: Th1 in active disease but Tr1 in remission.Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children.Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell TransplantationTreatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T CellsPoor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute
P2860
Q34188383-DF650A0E-5D60-4687-B3DC-47FAD43C7429Q35849039-3A1CAAC4-557B-428A-B333-B0AFA6D0CBF1Q35888698-B768195C-1FF5-4636-8063-F95BEFB7B6F0Q36480086-9A08F08B-C194-4B44-A1EA-51BF40E3E4F3Q36890569-6A06D43E-9E52-40FB-9182-EF27EC00C0CDQ37323929-FEA887A6-8F36-4AE9-AB1C-6DFDD7B13FD4Q37450543-23308FCB-FA0C-4514-BF61-BE71CF05BD2CQ37862042-9C969F67-D54B-4548-A099-DC50ACE5C1C3Q40656850-F63CC2F6-ABC4-4D0A-A5EF-327803CB7274Q45400120-4859C8EE-F540-4B87-826C-7DDBAFD468F2Q51981530-655A1800-1DA5-4ED8-A8F2-C098EB71E313Q57275302-BF394165-BDA5-480F-8225-874EEE782836Q57275304-A4F46188-59B8-4F81-9403-DEBB106A792EQ57700794-98F22D48-85B9-4725-8237-7BFC2E84F023
P2860
Immunotherapy for post-transplant lymphoproliferative disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunotherapy for post-transplant lymphoproliferative disease.
@ast
Immunotherapy for post-transplant lymphoproliferative disease.
@en
Immunotherapy for post-transplant lymphoproliferative disease.
@nl
type
label
Immunotherapy for post-transplant lymphoproliferative disease.
@ast
Immunotherapy for post-transplant lymphoproliferative disease.
@en
Immunotherapy for post-transplant lymphoproliferative disease.
@nl
prefLabel
Immunotherapy for post-transplant lymphoproliferative disease.
@ast
Immunotherapy for post-transplant lymphoproliferative disease.
@en
Immunotherapy for post-transplant lymphoproliferative disease.
@nl
P2093
P1476
Immunotherapy for post-transplant lymphoproliferative disease.
@en
P2093
Barbara Savoldo
Cliona M Rooney
Helen E Heslop
Karin C M Straathof
P2860
P304
P356
10.1046/J.1365-2141.2002.03594.X
P407
P577
2002-09-01T00:00:00Z